334 results on '"Fiocchi A."'
Search Results
2. Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy
3. Corrigendum to: Recurrence of Crohn’s Disease After Small Bowel Transplantation: Fact or Fiction
4. Recurrence of Crohn’s Disease After Small Bowel Transplantation: Fact or Fiction
5. Acupuncture in Inflammatory Bowel Disease
6. Mutual Regulation of TLR/NLR and CEACAM1 in the Intestinal Microvasculature: Implications for IBD Pathogenesis and Therapy
7. Geosocial Features and Loss of Biodiversity Underlie Variable Rates of Inflammatory Bowel Disease in a Large Developing Country: A Population-Based Study.
8. Network Medicine: A Mandatory Next Step for Inflammatory Bowel Disease
9. Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy.
10. Impact of Abdominal Visceral Adipose Tissue on Disease Outcome in Pediatric Crohn's Disease.
11. CADHERIN-11, AN ESSENTIAL REGULATOR OF CELL-CELL ADHESION UPREGULATED IN IBD PATIENTS, PLAYS ESSENTIAL ROLES IN PROMOTING FIBROBLAST ACTIVATION AND DEVELOPMENT OF INTESTINAL INFLAMMATION AND FIBROSIS.
12. Late-breaking news from the '4th International Meeting on Inflammatory Bowel Diseases' Capri, 2006.
13. Future of IBD pathogenesis: How much work is left to do?
14. 'Immune/non-immune cell interactions in intestinal inflammation' workshop.
15. T cell receptor Vβ gene expression in inflammatory bowel disease lamina propria lymphocytes: Evidence for altered Vβ gene usage.
16. ACTIVATED INTESTINAL MUSCLE CELLS PROMOTE PREADIPOCYTE MIGRATION: A NOVEL MECHANISM OF CREEPING FAT FORMATION IN CROHN'S DISEASE.
17. Signal Transducers and Activators of Transcription 3 Signaling Pathway: An Essential Mediator of Inflammatory Bowel Disease and Other Forms of Intestinal Inflammation.
18. Etiopathogenesis of inflammatory bowel disease: The importance of the pediatric perspective.
19. Estrogen Receptor β Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-β/Smad and TLR4/MyD88/NF-κB Signaling Pathways.
20. Eosinophil Depletion as a Potential Therapeutic Strategy in Acute and Chronic Intestinal Inflammation Based on a Dextran Sulfate Sodium Colitis Model.
21. Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics.
22. What is 'physiological' intestinal inflammation and how does it differ from 'pathological' inflammation?
23. Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis.
24. Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.
25. Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis.
26. Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study.
27. Lack of ATP2B1 in CD4+ T Cells Causes Colitis.
28. A Systematic Review on the Increasing Incidence of Inflammatory Bowel Disease in Southeast Asia: Looking Beyond the Urbanization Phenomenon.
29. Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.
30. Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.
31. The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis.
32. Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study.
33. Challenges in IBD Research 2024: Precision Medicine.
34. Challenges in IBD Research 2024: Novel Technologies.
35. Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model.
36. Revisiting the Role of Valeric Acid in Manipulating Ulcerative Colitis.
37. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
38. Glycolytic Activation of CD14+ Intestinal Macrophages Contributes to the Inflammatory Responses via Exosomal Membrane Tumor Necrosis Factor in Crohn's Disease.
39. Pro-inflammatory Cytokines Promote the Occurrence and Development of Colitis-associated Colorectal Cancer by Inhibiting miR-615-5p.
40. Density of Biopsy Sampling Required to Ensure Accurate Histological Assessment of Inflammation in Active Ulcerative Colitis.
41. Inhibition of Soluble Stem Cell Factor Promotes Intestinal Mucosal Repair.
42. Single-cell Expression Atlas Reveals Cell Heterogeneity in the Creeping Fat of Crohn's Disease.
43. Appendix and Ulcerative Colitis: a Key to Explaining the Pathogenesis and Directing Novel Therapies?
44. Predictors: How to Approach the Individualization of Treatment.
45. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.
46. Role of Energy Metabolism and Mitochondrial Function in Inflammatory Bowel Disease.
47. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.
48. Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients.
49. Caveolin-1 Alleviates Crohn's Disease–induced Intestinal Fibrosis by Inhibiting Fibroblasts Autophagy Through Modulating Sequestosome 1.
50. Development of a Personalized Intestinal Fibrosis Model Using Human Intestinal Organoids Derived From Induced Pluripotent Stem Cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.